Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of death related to liver diseases worldwide. Despite this, there is no specific treatment approved for the disease till now, which could be due to the poor understanding of the pathophysiology of this disease. In the past few decades, several scientists have speculated the root cause of NAFLD to be dysbalance in the gut microbiome resulting in a susceptibility to the inflammatory cascade in the liver. Herein, we hypothesize to fabricate a novel formulation containing prebiotic with probiotics which thereby would help in maintaining the gut homeostasis, and be used for the treatment of NAFLD. The proposed novel formulation would contain a Bifidobacterium sp. with Faecalibacterium prausnitzii in the presence of a dietary fibre having hepatoprotective activity. These two strains of probiotics would help in increasing the concentration of butyrate in the gut which in turn would inhibit intestinal inflammation and maintain gut integrity. The dietary fibre would serve a dual mechanism; firstly, it would act as a prebiotic helping in the proliferation of administered probiotics, and secondly, it would protect the liver via its own hepatoprotective action. This combinatorial approach would pave a new therapeutic avenue for the treatment of NAFLD.

非酒精性脂肪性肝病 (NAFLD) 是全球与肝病相关的主要死亡原因之一。尽管如此，到目前为止还没有批准用于该疾病的特定治疗方法，这可能是由于对该疾病的病理生理学了解不足所致。在过去的几十年里，几位科学家推测 NAFLD 的根本原因是肠道微生物组失衡，导致肝脏对炎症级联反应敏感。在此，我们假设制造一种含有益生元和益生菌的新配方，从而有助于维持肠道稳态，并用于治疗 NAFLD。提议的新制剂将包含双歧杆菌属。在存在具有保肝活性的膳食纤维的情况下，与 Faecalibacterium prausnitzii 一起使用。这两种益生菌菌株将有助于增加肠道中丁酸盐的浓度，进而抑制肠道炎症并保持肠道完整性。膳食纤维将起到双重作用；首先，它可以作为益生元帮助益生菌的增殖，其次，它可以通过自身的保肝作用保护肝脏。这种组合方法将为 NAFLD 的治疗开辟一条新的治疗途径。它会通过自身的保肝作用保护肝脏。这种组合方法将为 NAFLD 的治疗开辟一条新的治疗途径。它会通过自身的保肝作用保护肝脏。这种组合方法将为 NAFLD 的治疗开辟一条新的治疗途径。